Impact of Bep or Carboplatin Chemotherapy on Testicular Function and Sperm Nucleus of Subjects with Testicular Germ Cell Tumor
Young males have testicular germ cells tumors (TGCT) as the most common malignancy and its incidence is increasing in several countries. Besides unilateral orchiectomy (UO), the treatment of TGCT may include surveillance, radiotherapy, or chemotherapy (CT), basing on tumor histology and stage of dis...
Saved in:
| Published in | Frontiers in pharmacology Vol. 7; p. 122 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
Frontiers Media S.A
13.05.2016
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1663-9812 1663-9812 |
| DOI | 10.3389/fphar.2016.00122 |
Cover
Loading…
| Abstract | Young males have testicular germ cells tumors (TGCT) as the most common malignancy and its incidence is increasing in several countries. Besides unilateral orchiectomy (UO), the treatment of TGCT may include surveillance, radiotherapy, or chemotherapy (CT), basing on tumor histology and stage of disease. It is well known that both radio and CT may have negative effects on testicular function, affecting spermatogenesis, and sex hormones. Many reports investigated these aspects in patients treated with bleomycin, etoposide, and cisplatin (BEP), after UO. In contrast no data are available on the side effects of carboplatin treatment in these patients. We included in this study 212 consecutive subjects who undergone to sperm banking at our Andrology and Human Reproduction Unit after UO for TGCT. Hundred subjects were further treated with one or more BEP cycles (BEP-group), 54 with carboplatin (CARB group), and 58 were just surveilled (S-group). All patients were evaluated for seminal parameters, sperm aneuploidy, sperm DNA, sex hormones, volume of the residual testis at baseline (T0) and after 12 (T1) and 24 months (T2) from UO or end of CT. Seminal parameters, sperm aneuploidies, DNA status, gonadic hormones, and testicular volume at baseline were not different between groups. At T1, we observed a significant reduction of sperm concentration and sperm count in the BEP group versus baseline and versus both Carb and S-group. A significant increase of sperm aneuploidies was present at T1 in the BEP group. Similarly, the same group at 1 had altered sperm DNA integrity and fragmentation compared with baseline, S-group and Carb group. These alterations were persistent after 2 years from the end of BEP treatment. Despite a slight improvement at T2, the BEP group had still higher percentages of sperm aneuploidies than other groups. No impairment of sperm aneuploidies and DNA status were observed in the Carb group both after 1 and 2 years from the end of treatment. Despite preliminary, these data demonstrate that in selected patients with TGCTs CT with carboplatin represents a therapeutic option that that seems to not affect sex hormones, spermatogenesis, and sperm nucleus. |
|---|---|
| AbstractList | Young males have testicular germ cells tumours (TGCT) as the most common malignancy and its incidence is increasing in several countries. Besides unilateral orchiectomy (UO), the treatment of TGCT may include surveillance, radiotherapy or chemotherapy (CT), basing on tumour histology and stage of disease. It is well known that both radio and CT may have negative effects on testicular function, affecting spermatogenesis and sex hormones. Many reports investigated these aspects in patients treated with bleomycin, etoposide and cisplatin (BEP), after UO. In contrast no data are available on the side effects of carboplatin treatment in these patients. We included in this study 212 consecutive subjects who undergone to sperm banking at our Andrology and Human Reproduction Unit after UO for TGCT. Hundred subjects were further treated with one or more BEP cycles (BEP-group), 54 with carboplatin (Carb group) and 58 were just surveilled (S-group). All patients were evaluated for seminal parameters, sperm aneuploidy, sperm DNA, sex hormones, volume of the residual testis at baseline (T0) and after 12 (T1) and 24 months (T2) from UO or end of CT. Seminal parameters, sperm aneuploidies, DNA status, gonadic hormones and testicular volume at baseline were not different between groups. At T1 we observed a significant reduction of sperm concentration and sperm count in the BEP group versus baseline and versus both Carb and S- group. A significant increase of sperm aneuploidies was present at T1 in the BEP group. Similarly, the same group at 1 had altered sperm DNA integrity and fragmentation compared with baseline, S group and Carb group. These alterations were persistent after two years from the end of BEP treatment. Despite a slight improvement at T2, the BEP group had still higher percentages of sperm aneuploidies than other groups. No impairment of sperm aneuploidies and DNA status were observed in the Carb group both after one and two years from the end of treatment. Despite preliminary, these data demonstrate that in selected patients with TGCTs CT with carboplatin represents a therapeutic option that that seems to not affect sex hormones, spermatogenesis and sperm nucleus. Young males have testicular germ cells tumors (TGCT) as the most common malignancy and its incidence is increasing in several countries. Besides unilateral orchiectomy (UO), the treatment of TGCT may include surveillance, radiotherapy, or chemotherapy (CT), basing on tumor histology and stage of disease. It is well known that both radio and CT may have negative effects on testicular function, affecting spermatogenesis, and sex hormones. Many reports investigated these aspects in patients treated with bleomycin, etoposide, and cisplatin (BEP), after UO. In contrast no data are available on the side effects of carboplatin treatment in these patients. We included in this study 212 consecutive subjects who undergone to sperm banking at our Andrology and Human Reproduction Unit after UO for TGCT. Hundred subjects were further treated with one or more BEP cycles (BEP-group), 54 with carboplatin (CARB group), and 58 were just surveilled ( S -group). All patients were evaluated for seminal parameters, sperm aneuploidy, sperm DNA, sex hormones, volume of the residual testis at baseline (T0) and after 12 (T1) and 24 months (T2) from UO or end of CT. Seminal parameters, sperm aneuploidies, DNA status, gonadic hormones, and testicular volume at baseline were not different between groups. At T1, we observed a significant reduction of sperm concentration and sperm count in the BEP group versus baseline and versus both Carb and S -group. A significant increase of sperm aneuploidies was present at T1 in the BEP group. Similarly, the same group at 1 had altered sperm DNA integrity and fragmentation compared with baseline, S -group and Carb group. These alterations were persistent after 2 years from the end of BEP treatment. Despite a slight improvement at T2, the BEP group had still higher percentages of sperm aneuploidies than other groups. No impairment of sperm aneuploidies and DNA status were observed in the Carb group both after 1 and 2 years from the end of treatment. Despite preliminary, these data demonstrate that in selected patients with TGCTs CT with carboplatin represents a therapeutic option that that seems to not affect sex hormones, spermatogenesis, and sperm nucleus. Young males have testicular germ cells tumors (TGCT) as the most common malignancy and its incidence is increasing in several countries. Besides unilateral orchiectomy (UO), the treatment of TGCT may include surveillance, radiotherapy, or chemotherapy (CT), basing on tumor histology and stage of disease. It is well known that both radio and CT may have negative effects on testicular function, affecting spermatogenesis, and sex hormones. Many reports investigated these aspects in patients treated with bleomycin, etoposide, and cisplatin (BEP), after UO. In contrast no data are available on the side effects of carboplatin treatment in these patients. We included in this study 212 consecutive subjects who undergone to sperm banking at our Andrology and Human Reproduction Unit after UO for TGCT. Hundred subjects were further treated with one or more BEP cycles (BEP-group), 54 with carboplatin (CARB group), and 58 were just surveilled (S-group). All patients were evaluated for seminal parameters, sperm aneuploidy, sperm DNA, sex hormones, volume of the residual testis at baseline (T0) and after 12 (T1) and 24 months (T2) from UO or end of CT. Seminal parameters, sperm aneuploidies, DNA status, gonadic hormones, and testicular volume at baseline were not different between groups. At T1, we observed a significant reduction of sperm concentration and sperm count in the BEP group versus baseline and versus both Carb and S-group. A significant increase of sperm aneuploidies was present at T1 in the BEP group. Similarly, the same group at 1 had altered sperm DNA integrity and fragmentation compared with baseline, S-group and Carb group. These alterations were persistent after 2 years from the end of BEP treatment. Despite a slight improvement at T2, the BEP group had still higher percentages of sperm aneuploidies than other groups. No impairment of sperm aneuploidies and DNA status were observed in the Carb group both after 1 and 2 years from the end of treatment. Despite preliminary, these data demonstrate that in selected patients with TGCTs CT with carboplatin represents a therapeutic option that that seems to not affect sex hormones, spermatogenesis, and sperm nucleus. Young males have testicular germ cells tumors (TGCT) as the most common malignancy and its incidence is increasing in several countries. Besides unilateral orchiectomy (UO), the treatment of TGCT may include surveillance, radiotherapy, or chemotherapy (CT), basing on tumor histology and stage of disease. It is well known that both radio and CT may have negative effects on testicular function, affecting spermatogenesis, and sex hormones. Many reports investigated these aspects in patients treated with bleomycin, etoposide, and cisplatin (BEP), after UO. In contrast no data are available on the side effects of carboplatin treatment in these patients. We included in this study 212 consecutive subjects who undergone to sperm banking at our Andrology and Human Reproduction Unit after UO for TGCT. Hundred subjects were further treated with one or more BEP cycles (BEP-group), 54 with carboplatin (CARB group), and 58 were just surveilled (S-group). All patients were evaluated for seminal parameters, sperm aneuploidy, sperm DNA, sex hormones, volume of the residual testis at baseline (T0) and after 12 (T1) and 24 months (T2) from UO or end of CT. Seminal parameters, sperm aneuploidies, DNA status, gonadic hormones, and testicular volume at baseline were not different between groups. At T1, we observed a significant reduction of sperm concentration and sperm count in the BEP group versus baseline and versus both Carb and S-group. A significant increase of sperm aneuploidies was present at T1 in the BEP group. Similarly, the same group at 1 had altered sperm DNA integrity and fragmentation compared with baseline, S-group and Carb group. These alterations were persistent after 2 years from the end of BEP treatment. Despite a slight improvement at T2, the BEP group had still higher percentages of sperm aneuploidies than other groups. No impairment of sperm aneuploidies and DNA status were observed in the Carb group both after 1 and 2 years from the end of treatment. Despite preliminary, these data demonstrate that in selected patients with TGCTs CT with carboplatin represents a therapeutic option that that seems to not affect sex hormones, spermatogenesis, and sperm nucleus.Young males have testicular germ cells tumors (TGCT) as the most common malignancy and its incidence is increasing in several countries. Besides unilateral orchiectomy (UO), the treatment of TGCT may include surveillance, radiotherapy, or chemotherapy (CT), basing on tumor histology and stage of disease. It is well known that both radio and CT may have negative effects on testicular function, affecting spermatogenesis, and sex hormones. Many reports investigated these aspects in patients treated with bleomycin, etoposide, and cisplatin (BEP), after UO. In contrast no data are available on the side effects of carboplatin treatment in these patients. We included in this study 212 consecutive subjects who undergone to sperm banking at our Andrology and Human Reproduction Unit after UO for TGCT. Hundred subjects were further treated with one or more BEP cycles (BEP-group), 54 with carboplatin (CARB group), and 58 were just surveilled (S-group). All patients were evaluated for seminal parameters, sperm aneuploidy, sperm DNA, sex hormones, volume of the residual testis at baseline (T0) and after 12 (T1) and 24 months (T2) from UO or end of CT. Seminal parameters, sperm aneuploidies, DNA status, gonadic hormones, and testicular volume at baseline were not different between groups. At T1, we observed a significant reduction of sperm concentration and sperm count in the BEP group versus baseline and versus both Carb and S-group. A significant increase of sperm aneuploidies was present at T1 in the BEP group. Similarly, the same group at 1 had altered sperm DNA integrity and fragmentation compared with baseline, S-group and Carb group. These alterations were persistent after 2 years from the end of BEP treatment. Despite a slight improvement at T2, the BEP group had still higher percentages of sperm aneuploidies than other groups. No impairment of sperm aneuploidies and DNA status were observed in the Carb group both after 1 and 2 years from the end of treatment. Despite preliminary, these data demonstrate that in selected patients with TGCTs CT with carboplatin represents a therapeutic option that that seems to not affect sex hormones, spermatogenesis, and sperm nucleus. |
| Author | Foresta, Carlo Palego, Pierfrancesco Sartini, Barbara Garolla, Andrea Finos, Livio Selice, Riccardo Ghezzi, Marco Berretta, Massimiliano Bottacin, Alberto Cosci, Ilaria |
| AuthorAffiliation | 1 Unit of Andrology and Reproductive Medicine, Department of Medicine, University of Padova Padova, Italy 4 Department of Statistical Sciences, University of Padova Padova, Italy 3 Department of Medical Oncology, CRO Aviano National Cancer Institute IRCCS Aviano, Italy 2 Istituto Oncologico Veneto – Istituto di Ricovero e Cura a Carattere Scientifico Padova, Italy |
| AuthorAffiliation_xml | – name: 1 Unit of Andrology and Reproductive Medicine, Department of Medicine, University of Padova Padova, Italy – name: 2 Istituto Oncologico Veneto – Istituto di Ricovero e Cura a Carattere Scientifico Padova, Italy – name: 4 Department of Statistical Sciences, University of Padova Padova, Italy – name: 3 Department of Medical Oncology, CRO Aviano National Cancer Institute IRCCS Aviano, Italy |
| Author_xml | – sequence: 1 givenname: Marco surname: Ghezzi fullname: Ghezzi, Marco – sequence: 2 givenname: Massimiliano surname: Berretta fullname: Berretta, Massimiliano – sequence: 3 givenname: Alberto surname: Bottacin fullname: Bottacin, Alberto – sequence: 4 givenname: Pierfrancesco surname: Palego fullname: Palego, Pierfrancesco – sequence: 5 givenname: Barbara surname: Sartini fullname: Sartini, Barbara – sequence: 6 givenname: Ilaria surname: Cosci fullname: Cosci, Ilaria – sequence: 7 givenname: Livio surname: Finos fullname: Finos, Livio – sequence: 8 givenname: Riccardo surname: Selice fullname: Selice, Riccardo – sequence: 9 givenname: Carlo surname: Foresta fullname: Foresta, Carlo – sequence: 10 givenname: Andrea surname: Garolla fullname: Garolla, Andrea |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27242529$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kk1v1DAQhi1URD_onRPykcsu_oqTXJAgou1KFRy6nK2JM2m8SuLgJEW98Ntxdlu0RcIXW-OZ57Vn3nNy0vseCXnH2VrKLP9YDw2EtWBcrxnjQrwiZ1xrucozLk6Ozqfkchx3LC6Z51KrN-RUpEKJRORn5PemG8BO1Nf0Cw7UB1pAKP3QwuR6WjTY-anBAMMj9T3d4jg5O7cQ6NXc28nFGPQVvRswdPTbbFucx4V1N5c7tNNIf7mpOS67XhILbFu6nTsf3pLXNbQjXj7tF-TH1ddtcbO6_X69KT7frqzSYloB2rzWmidpLTSCyrOEiZRlPCsrHT-DZZVyXotUM60ApbVKKMWYrlNAlFpekM2BW3nYmSG4DsKj8eDMPuDDvYEQ39iiSTFJVBVpVZarUrNSQ5ZAWmuVAfJSRNanA2uYyw4ri_0UoH0BfXnTu8bc-wejMp0kPI2AD0-A4H_OsTemc6ONPYEe_TwanuZScMnVovX-WOuvyPMAY4I-JNjgxzFgbaybYBlMlHat4cwsZjF7s5jFLGZvlljI_il8Zv-35A8-lsPB |
| CitedBy_id | crossref_primary_10_1007_s40619_019_00535_y crossref_primary_10_3390_antiox8100449 crossref_primary_10_1200_JCO_20_02713 crossref_primary_10_3389_fendo_2018_00506 crossref_primary_10_1097_MOU_0000000000000527 crossref_primary_10_1186_s12610_018_0082_2 crossref_primary_10_33590_emj_10312990 crossref_primary_10_3390_life13030815 crossref_primary_10_1097_MOU_0000000000000530 crossref_primary_10_1111_cts_13866 crossref_primary_10_1016_j_mam_2024_101308 crossref_primary_10_1007_s40618_024_02435_x crossref_primary_10_1111_andr_13741 crossref_primary_10_1016_j_biopha_2021_112040 crossref_primary_10_29252_ijrm_15_6_331 crossref_primary_10_3390_medicina59071226 crossref_primary_10_3389_fendo_2019_00408 crossref_primary_10_1093_annonc_mdz017 crossref_primary_10_1111_joim_13778 crossref_primary_10_17650_1726_9776_2023_19_1_115_128 crossref_primary_10_1080_01635581_2020_1757128 crossref_primary_10_1111_bju_14455 crossref_primary_10_1016_j_xfss_2024_10_003 crossref_primary_10_1089_jayao_2019_0164 crossref_primary_10_1016_j_fertnstert_2016_11_015 crossref_primary_10_3389_fonc_2020_00232 crossref_primary_10_1089_jayao_2016_0084 crossref_primary_10_1093_annonc_mdx360 crossref_primary_10_1016_j_amjmed_2017_01_010 crossref_primary_10_1007_s40618_022_01741_6 |
| Cites_doi | 10.1080/02841860701518058 10.1016/j.fertnstert.2009.05.068 10.4103/1008-682X.122194 10.1002/(SICI)1098-2280(1996)28 10.1111/j.2047-2927.2014.00250.x 10.1016/S0140-6736(05)66984-X 10.1371/journal.pone.0060922 10.1200/JCO.2009.26.4655 10.1016/j.fertnstert.2012.09.006 10.1016/j.eururo.2006.08.024 10.1056/NEJMra0801454 10.1093/oxfordjournals.humrep.a019255 10.1016/j.fertnstert.2013.05.018 10.1016/S0140-6736(02)09606-X 10.1093/annonc/mdq177 10.1200/JCO.2011.36.2434 10.1111/j.1365-2605.2010.01134.x 10.1093/humrep/dem389 10.1016/j.eururo.2013.11.004 10.1093/humrep/16.6.1204 10.1016/j.febslet.2006.10.016 10.1200/JCO.2011.35.7970 10.3389/fendo.2012.00172 10.3389/fendo.2014.00172 10.1038/nrc1296 10.1093/annonc/mdt304 10.1007/s12032-013-0661-1 10.1111/andr.12102 10.1071/RD9950799 |
| ContentType | Journal Article |
| Copyright | Copyright © 2016 Ghezzi, Berretta, Bottacin, Palego, Sartini, Cosci, Finos, Selice, Foresta and Garolla. 2016 Ghezzi, Berretta, Bottacin, Palego, Sartini, Cosci, Finos, Selice, Foresta and Garolla |
| Copyright_xml | – notice: Copyright © 2016 Ghezzi, Berretta, Bottacin, Palego, Sartini, Cosci, Finos, Selice, Foresta and Garolla. 2016 Ghezzi, Berretta, Bottacin, Palego, Sartini, Cosci, Finos, Selice, Foresta and Garolla |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.3389/fphar.2016.00122 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1663-9812 |
| ExternalDocumentID | oai_doaj_org_article_7e554d11fd894b60b6a85a7f648ae1b2 PMC4865517 27242529 10_3389_fphar_2016_00122 |
| Genre | Journal Article |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E O5R O5S OK1 P2P PGMZT RNS RPM IPNFZ NPM RIG 7X8 5PM |
| ID | FETCH-LOGICAL-c462t-aec9f66157f26ea49850270818bd6272ebd711f276064ae3cc4244006f7aee363 |
| IEDL.DBID | M48 |
| ISSN | 1663-9812 |
| IngestDate | Wed Aug 27 01:21:26 EDT 2025 Thu Aug 21 14:12:59 EDT 2025 Thu Jul 10 18:34:17 EDT 2025 Mon Jul 21 06:04:42 EDT 2025 Tue Jul 01 02:25:03 EDT 2025 Thu Apr 24 23:04:57 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | BEP chemotherapy carboplatin fertility testis cancer |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c462t-aec9f66157f26ea49850270818bd6272ebd711f276064ae3cc4244006f7aee363 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Giovanni Li Volti, University of Catania, Italy Reviewed by: Loredana Gandini, Sapienza University of Rome, Italy; Gaetano Facchini, Istituto Nazionale Tumori Fondazione G. Pascale, Italy This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology |
| OpenAccessLink | https://doaj.org/article/7e554d11fd894b60b6a85a7f648ae1b2 |
| PMID | 27242529 |
| PQID | 1793213142 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_7e554d11fd894b60b6a85a7f648ae1b2 pubmedcentral_primary_oai_pubmedcentral_nih_gov_4865517 proquest_miscellaneous_1793213142 pubmed_primary_27242529 crossref_citationtrail_10_3389_fphar_2016_00122 crossref_primary_10_3389_fphar_2016_00122 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2016-05-13 |
| PublicationDateYYYYMMDD | 2016-05-13 |
| PublicationDate_xml | – month: 05 year: 2016 text: 2016-05-13 day: 13 |
| PublicationDecade | 2010 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in pharmacology |
| PublicationTitleAlternate | Front Pharmacol |
| PublicationYear | 2016 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Berretta (B1) 2014; 1 Oliver (B17) 2005; 366 Garolla (B9) 2012; 3 De Mas (B4) 2001; 16 Jeruss (B12) 2009; 360 Hassold (B10) 1996; 28 Choy (B3) 2013; 100 Dieckmann (B5) 2011; 29 Znaor (B32) 2014; 65 Eggert-Kruse (B6) 1996; 11 O’Flaherty (B15) 2010; 94 Paoli (B19) 2015; 3 Schmoll (B25) 2010; 21(Suppl. 5) Tempest (B28) 2008; 23 Zhou (B31) 2004; 4 Bujan (B2) 2013; 100 Garolla (B8) 2013; 99 Oldenburg (B16) 2013; 24(Suppl. 6) Li (B13) 2006; 580 Patassini (B20) 2013; 8 Ping (B21) 2014; 16 Liu (B14) 2015; 3 Oliver (B18) 2011; 29 World Health Organization [WHO] (B30) 1999 Robbins (B23) 1995; 7 Huyghe (B11) 2007; 51 Thomson (B29) 2002; 360 Ferlin (B7) 2014; 5 Selice (B26) 2011; 34 Schagen (B24) 2008; 47 Stenning (B27) 2011; 29 Quinton (B22) 2013; 30 |
| References_xml | – volume: 47 start-page: 63 year: 2008 ident: B24 article-title: Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. publication-title: Acta Oncol. doi: 10.1080/02841860701518058 – volume: 94 start-page: 1374 year: 2010 ident: B15 article-title: Impact of chemotherapeutics and advanced testicular cancer or Hodgkin lymphoma on sperm deoxyribonucleic acid integrity. publication-title: Fertil. Steril. doi: 10.1016/j.fertnstert.2009.05.068 – year: 1999 ident: B30 publication-title: WHO Laboratory Manual for the Examination of Human Semen, and Sperm-Cervical Mucus Interaction. – volume: 16 start-page: 107 year: 2014 ident: B21 article-title: Fertility outcome of patients with testicular tumor: before and after treatment. publication-title: Asian J. Androl. doi: 10.4103/1008-682X.122194 – volume: 28 start-page: 167 year: 1996 ident: B10 article-title: Human aneuploidy : incidence, origin and etiology. publication-title: Environ. Mol. Mutagen doi: 10.1002/(SICI)1098-2280(1996)28 – volume: 3 start-page: 122 year: 2015 ident: B19 article-title: Testicular cancer and sperm DNA damage: short- and long-term effects of antineoplastic treatment. publication-title: Andrology doi: 10.1111/j.2047-2927.2014.00250.x – volume: 366 start-page: 293 year: 2005 ident: B17 article-title: Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. publication-title: Lancet doi: 10.1016/S0140-6736(05)66984-X – volume: 8 issue: 922 year: 2013 ident: B20 article-title: Molecular karyotyping of human single sperm by array-comparative genomic hybridization. publication-title: PLoS ONE doi: 10.1371/journal.pone.0060922 – volume: 29 start-page: 957 year: 2011 ident: B18 article-title: Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE 19/EORTC 30982 study. publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2009.26.4655 – volume: 99 start-page: 125 year: 2013 ident: B8 article-title: Association, prevalence and clearance of human papillomavirus and antisperm antibodies in infected semen samples from infertile patients. publication-title: Fertil. Steril. doi: 10.1016/j.fertnstert.2012.09.006 – volume: 51 start-page: 621 year: 2007 ident: B11 article-title: Testicular cancer variations in time and space in Europe. publication-title: Eur. Urol. doi: 10.1016/j.eururo.2006.08.024 – volume: 360 start-page: 902 year: 2009 ident: B12 article-title: Preservation of fertility in patients with cancer. publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra0801454 – volume: 11 start-page: 784 year: 1996 ident: B6 article-title: The Acridine Orange test: a clinically relevant screening method for sperm quality during infertility investigation? publication-title: Hum. Reprod. doi: 10.1093/oxfordjournals.humrep.a019255 – volume: 100 start-page: 1187 year: 2013 ident: B3 article-title: The determination of reproductive safety in men during and after cancer treatment. publication-title: Fertil. Steril. doi: 10.1016/j.fertnstert.2013.05.018 – volume: 360 start-page: 361 year: 2002 ident: B29 article-title: Semen quality and spermatozoal DNA integrity in survivors of childhood cancer: a case-control study. publication-title: Lancet doi: 10.1016/S0140-6736(02)09606-X – volume: 21(Suppl. 5) start-page: 147 year: 2010 ident: B25 article-title: Testicular non seminoma: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. publication-title: Ann. Oncol. doi: 10.1093/annonc/mdq177 – volume: 29 start-page: 4210 year: 2011 ident: B27 article-title: Carboplatin in clinical stage I seminoma: a valuable option for patient management. publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2011.36.2434 – volume: 34 start-page: e511 year: 2011 ident: B26 article-title: Effects of endogenous FSH on normal human spermatogenesis in adults. publication-title: Int. J. Androl. doi: 10.1111/j.1365-2605.2010.01134.x – volume: 23 start-page: 251 year: 2008 ident: B28 article-title: Sperm aneuploidy frequencies analysed before and after chemotherapy in testicular cancer and Hodgkin’s lymphoma patients. publication-title: Hum. Reprod. doi: 10.1093/humrep/dem389 – volume: 65 start-page: 1095 year: 2014 ident: B32 article-title: International variations and trends in testicular cancer incidence and mortality. publication-title: Eur. Urol. doi: 10.1016/j.eururo.2013.11.004 – volume: 16 start-page: 1204 year: 2001 ident: B4 article-title: Increased aneuploidy in spermatozoa from testicular tumour patients after chemotherapy with cisplatin, etoposide and bleomycin. publication-title: Hum. Reprod. doi: 10.1093/humrep/16.6.1204 – volume: 580 start-page: 6161 year: 2006 ident: B13 article-title: Oxidative stress induces H2AX phosphorylation in human spermatozoa. publication-title: FEBS Lett. doi: 10.1016/j.febslet.2006.10.016 – volume: 29 start-page: 2944 year: 2011 ident: B5 article-title: Carboplatin does not prevent contralateral testicular tumors in patients with seminoma. publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2011.35.7970 – volume: 3 issue: 172 year: 2012 ident: B9 article-title: Testicular cancer and HPV semen infection. publication-title: Front. Endocrinol. (Lausanne) doi: 10.3389/fendo.2012.00172 – volume: 5 issue: 172 year: 2014 ident: B7 article-title: Testis cancer: genes, environment, hormones. publication-title: Front. Endocrinol. (Lausanne) doi: 10.3389/fendo.2014.00172 – volume: 4 start-page: 216 year: 2004 ident: B31 article-title: Targeting the checkpoint kinases: chemosensitization versus chemoprotection. publication-title: Nat. Rev. Cancer doi: 10.1038/nrc1296 – volume: 100 start-page: 673 year: 2013 ident: B2 article-title: Impact of chemotherapy and radiotherapy for testicular germ cell tumors on spermatogenesis and sperm DNA: a multicenter prospective study from the CECOS network. publication-title: Fertil. Steril. doi: 10.1016/j.fertnstert.2013.05.018 – volume: 24(Suppl. 6) start-page: 125 year: 2013 ident: B16 article-title: Testicular seminoma and non-seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. publication-title: Ann. Oncol. doi: 10.1093/annonc/mdt304 – volume: 1 issue: e133 year: 2014 ident: B1 article-title: Editorial – The new oncologic challenges in the 3RD millennium. publication-title: W.C.R.J. – volume: 30 issue: 661 year: 2013 ident: B22 article-title: A comparison of measured and estimated glomerular filtration rate for carboplatin dose calculation in stage I testicular seminoma. publication-title: Med. Oncol. doi: 10.1007/s12032-013-0661-1 – volume: 3 start-page: 1104 year: 2015 ident: B14 article-title: The effects of chemotherapy with bleomycin, etoposide and cis-platinum on telomeres in rat male germ cells. publication-title: Andrology doi: 10.1111/andr.12102 – volume: 7 start-page: 799 year: 1995 ident: B23 article-title: Three-probe fluorescent in-situ hybridization to assess chromosome X, Y and 8 aneuploidy in sperm of 14 men from two healthy groups: evidence for a paternal age effect on sperm aneuploidy. publication-title: Reprod. Fertil. Dev. doi: 10.1071/RD9950799 |
| SSID | ssj0000399364 |
| Score | 2.262072 |
| Snippet | Young males have testicular germ cells tumors (TGCT) as the most common malignancy and its incidence is increasing in several countries. Besides unilateral... Young males have testicular germ cells tumours (TGCT) as the most common malignancy and its incidence is increasing in several countries. Besides unilateral... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 122 |
| SubjectTerms | BEP Carboplatin chemotherapy Fertility Pharmacology testis cancer |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Na9swFBejp13GvpetGyqMwqAmlSxL9tFxnSXDsY0js-5kJEumg-KWNT30sr99kuymyRjbZRcf5Cdb6D29D97T7wHwsZU-EYQQTwjVeoSxwAsRo56gijKtlFQug7_K6aImX86D851WX7YmbIAHHjZuyrQxeAqhToURkfRUUhEGgnWUhEIj6bSvsXk7wZTTwdbuUjLkJU0UFk276wth8T-RSz5gvGeHHFz_n3zM30sld2zP_Cl4MjqNMB4W-ww80v1zcFwOqNN3J5A_XKK6OYHHsHzAo757AX4uV2WccFjM4SwtYVHBJK5mRZnFfJlDi4lQ8EVaxeU3WOSQp2u-TOosruC8zl2JCYzzM7gu02oF8zrJ0nptvzW2SlnDr0u-2J322RImaZZBXq-K6iWo5ylPFt7YdsFrCcUbT-g26ozZDliHqRYkCgMTu1roO6koZlhLxQw_MDOxDxHab1t7Wc6c3o4JrX3qvwIH_VWv3wAYqK4NZSiEceuIL5E41ZHyzUMgoSKJJ2B6z4SmHTHJbWuMy8bEJpZtjWNbY9nWOLZNwKftjOsBj-MvtDPL1y2dRdJ2A0a-mlG-mn_J1wQc3UtFY06eTaeIXl_d3jRWtWHkI2JoXg9Ssv2V2SajDHE0AWxPfvbWsv-m_37h0L2JvSqM2Nv_sfh34LHdDlvtgPxDcLD5cavfGydqIz-48_IL9rIR2g priority: 102 providerName: Directory of Open Access Journals |
| Title | Impact of Bep or Carboplatin Chemotherapy on Testicular Function and Sperm Nucleus of Subjects with Testicular Germ Cell Tumor |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/27242529 https://www.proquest.com/docview/1793213142 https://pubmed.ncbi.nlm.nih.gov/PMC4865517 https://doaj.org/article/7e554d11fd894b60b6a85a7f648ae1b2 |
| Volume | 7 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9QwEA9yvvgifrt-HBHkQLh6lzRN2gcRb3E9hTsO3IV7K5Mm9YS1re0uuC_-7c6kvd1bWQRfCm2TfmQy85tJMr8w9rqwsQKlVATgikgZk0SpMDoC7bTxzlkXZvDPzvXpTH25TC436dFDA3Y7QzvaT2rWzt_--rl6jwr_jiJOxNujsrkCovYUYV5BokG-jbhkaCOHs8HZD3aZsDjwSQmE2ShDaOvnLXc-ZAunAp3_Lh_076WUN7Bpco_dHZxK_qHvBffZLV89YAcXPSv16pBPN0lW3SE_4BcbvurVQ_b7c8iU5HXJT3zD65aPobV1Q6vkKk6MAkOW1orXFZ8SLUdYvMoniIkkVw6V418btPH8nOiRlx09C00SjfF0nIZ6b1b7RAXHfj7n0-WPun3EZpOP0_FpNGzLEBVKy0UEvshKhPXElFJ7UFmaYGxL1HjWaWmkt84IUUqDsZECHxcFJdOhdpcGvI91_JjtVXXlnzKeuLJIbQqAbp-KrYBjn7kYDyDAZVaO2NG1EPJi4CynrTPmOcYuJLY8iC0nseVBbCP2Zl2j6fk6_lH2hOS6LkdM2-FC3X7LB8XNjUeHy-H_uDRTVh9bDWkCptQqBS_oE19d94ocNZOmW6Dy9bLLyfRJEQuFZZ70vWT9KmwmNJYyGzGz1X-2vmX7TvX9KrB_K0olFubZf_zoc3aHTmjRg4hfsL1Fu_Qv0Zda2P0wBrEfFOUPy34ffQ |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+Bep+or+Carboplatin+Chemotherapy+on+Testicular+Function+and+Sperm+Nucleus+of+Subjects+with+Testicular+Germ+Cell+Tumor&rft.jtitle=Frontiers+in+pharmacology&rft.au=Ghezzi%2C+Marco&rft.au=Berretta%2C+Massimiliano&rft.au=Bottacin%2C+Alberto&rft.au=Palego%2C+Pierfrancesco&rft.date=2016-05-13&rft.issn=1663-9812&rft.eissn=1663-9812&rft.volume=7&rft_id=info:doi/10.3389%2Ffphar.2016.00122&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fphar_2016_00122 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon |